BMS Buys iPierian and its Anti-Tau Programme for a Potential US$725 M

By Heather Cartwright

Pharma Deals Review: Vol 2014 Issue 5 (Table of Contents)

Published: 28 May-2014

DOI: 10.3833/pdr.v2014.i5.2031     ISSN: 1756-7874

Section: Mergers & Acquisitions



Seven months after separating into two companies, neurodegenerative disease specialist iPierian has agreed to be acquired by Bristol-Myers Squibb (BMS) for US$175 M in cash upfront plus potential milestone payments of up to US$550 M and royalties...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details